Protagonist治疗公司前不久宣布,欧洲药物管理局(EMA)已授予PTG-300治疗真性红细胞增多症(polycythemia vera)的孤儿药资格认定。PTG-300是天然激素hepcidin的一种可注射合成肽模拟物,此前已获得美国食品和药物管理局(FDA)授予治疗真性红细胞增多症的孤儿药资格认定。 Protagonist治疗公司前不久宣布,欧洲药物管理局(...
Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.doi:10.1200/JCO.2022.40.16_suppl.700317003#Background:Polycythemia (PV) patients with hematocrit (HCT) levels > 45% are at an increased risk of thrombosis and are treated with therapeutic phlebotomy (TP) alone or ...
参考资料:[1] Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera. Retrieved 2020-12-03, from PR Newswire 送TA礼物 来自Android客户端1楼2020-12-05 08:08回复 ...
Key words: Hepcidin, Hematocrit, Rusfertide, PTG-300, Polycythemia Vera, PV, Therapeutic Phlebotomy Download: Download high-res image (567KB) Download: Download full-size image Figure 1. Disclosures Gupta: Protagonist Therapeutics: Current Employment. Valone: Protagonist Therapeutics: Consultancy...
Context: Polycythemia vera (PV) patients are routinely treated with periodic therapeutic phlebotomy (TP) alone or combined with cytoreductive therapy to maintain hematocrit (HCT) <45% and reduce the incidence of thrombosis. TP may not adequately control HCT and results in iron deficiency. Rusfertide...
PTG-300疗法也可能对其他疾病有潜在益处,比如骨髓增生异常综合征(myelodysplastic syndrome,MDS)、遗传性血色沉着病(hereditary hemochromatosis,HH)、真性红细胞增多症(polycythemia vera,PCV)、亲铁性感染(siderophilic infections)及肝纤维化(liver fibrosis),这为其未来开发提供了额外机会。铁调素是一种天然肽类激素,是...
VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).662222Background:聽PV is a myeloproliferative neoplasm characterized by overproduction of red blood cells and increased risk of thrombosis. Patients may require ...
Objectives Rusfertide is a potent peptide mimetic of hepcidin being investigated for the treatment of polycythemia vera. This randomized, placebo-controlled, double-blind study evaluated the safety, pharmacokinetics, and pharmacodynamics of single and repeated subcutaneous doses of an aqueous formulation ...
Polycythemia vera (PV) patients are treated with periodic therapeutic phlebotomy (TP) in order to maintain hematocrit levels 45%, thereby potentially increasing their risk of thrombosis. Symptomatic iron deficiency represents a challenge in PV as it is commonly present at diagnosis [Ginzburg Leukemia ...
Polycythemia vera (PV) patients are treated with periodic therapeutic phlebotomy (TP) alone or in combination with either hydroxyurea (HU), ruxolitinib (RUX) or interferon (IFN) to maintain hematocrit (HCT) levels below 45% as per NCCN guidelines. Since patients are seen periodically, PV ...